Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Giacomazzi, Juliana ^a,b   Graudenz, Marcia S ^a,b,c   Osorio, Cynthia A B T ^d   Koehler Santos, Patricia ^a   Palmero, Edenir I ^e   Zagonel Oliveira, Marcelo ^b   Michelli, Rodrigo A D ^e   Neto, Cristovam Scapulatempo ^e   Fernandes, Gabriela C ^e   Achatz, Maria Isabel W S ^f   Martel Planche, Ghyslaine ^g   Soares, Fernando A ^d   Caleffi, Maira ^h   Goldim, José Roberto ^a   Hainaut, Pierre ^g,i   Camey, Suzi A ^b   Ashton Prolla, Patricia ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Instituto de Patologia   (Brazil)

^d A C CAMARGO CANCER CENTER   (Brazil)

^e BARRETOS CANCER HOSPITAL   (Brazil)

^f Pathology Service HCACC   (Brazil)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h HOSPITAL MOINHOS DE VENTO   (Brazil)

ⁱ INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; BRAZIL; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER PATIENT; CHEK2 GENE; CONTROLLED STUDY; EXON; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE; ONCOGENE TP53; PREVALENCE; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; GENETICS; MIDDLE AGED; MISSENSE MUTATION; PEDIGREE;

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; BRAZIL; BREAST NEOPLASMS; FEMALE; HAPLOTYPES; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; PEDIGREE; PREVALENCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903292688     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099893     Document Type: Article

References (31)

1. Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238. (Pubitemid 120031831)
2. Borresen A, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, et al. (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52: 3234-3236.
3. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, et al. (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52: 2984-2986.
4. Lalloo F, Varley J, Moran A, Ellis D, O'dair L, et al. (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42: 1143-1150.
5. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, et al. (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27: 1250-1256.
6. Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, et al. (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8: 563-567.
7. Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, et al. (2012) Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 14: R61.
8. McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, et al. (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 11: 607-613.
9. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, et al. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 98: 9330-9335. (Pubitemid 32743916)
10. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, et al. (2001) An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 86: 4970-4973. (Pubitemid 33020551)
11. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, et al. (2007) The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumenilike syndromes in Brazilian families. Cancer Lett 245: 96-102. (Pubitemid 44959345)
12. Palmero EI, Schuler-Faccini L, Caleffi M, Achatz MI, Olivier M, et al. (2008) Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 261: 21-25.
13. Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, et al. (2013) Impact of Neonatal Screening and Surveillance for the TP53 R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. J Clin Oncol 31: 2619-2626.
14. Seidinger AL, Mastellaro MJ, Paschoal Fortes F, Godoy Assumpção J, Aparecida Cardinalli I, et al. (2011) Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil. Cancer 117: 2228-2235.
15. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, et al. (2002) A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9: 12-16. (Pubitemid 34049172)
16. Webb BA, Chimenti M, Jacobson MP, Barber DL (2011) Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 11: 671-677.
17. Hafsi H, Hainaut P (2011) Redox control and interplay between p53 isoforms: roles in the regulation of basal p53 levels, cell fate, and senescence. Antioxid Redox Signal 15: 1655-1667.
18. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, et al. (2010) Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 31: 143-150.
19. International Agency for Research on Cancer (IARC) Database (2012) Available: http://p53.iarc.fr/p53Sequences.aspx.Accessed July 1, 2012.
20. Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, et al. (2008) Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 8: 357.
21. Gomes MC, Kotsopoulos J, de Almeida GL, Costa MM, Vieira R, et al. (2012) The R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 10: 3.
22. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, et al. (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72: 1308-1314. (Pubitemid 36530019)
23. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996; 14: 1730-6.
24. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, et al. (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108(44): 18032-18037.
25. da Silva EM, Achatz MI, Martel-Planche G, Montagnini AL, Olivier M, et al. (2011) TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child: evidence for chimerism involving a common mutant founder haplotype: case report. BMC Cancer 11: 449.
26. Instituto Brasileiro de Geografia e Estatística (IBGE) - Unidades da Federação (2012) Available: http://www.ibge.gov.br/home/ geociencias/areaterritorial/principal.shtm.Accessed July 1, 2012.
27. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, et al. (2003) Li- Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63: 6643-6650. (Pubitemid 37322942)
28. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, et al. (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70: 4795-4800.
29. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, et al. (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27: e108-109.
30. Haikel RL Jr, Mauad EC, Silva TB, Mattos JS, Chala LF, et al. (2012) Mammography-based screening program: preliminary results from a first 2-year round in a Brazilian region using mobile and fixed units. BMC Womens Health 12: 32.
31. Giacomazzi J, Selistre S, Duarte J, Ribeiro JP, Vieira PJ, et al. (2013) TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient. BMC Cancer 13: 187.